T1	CHEM 46 58	Pomalidomida
#1	AnnotatorNotes T1	C2347624; pomalidomide; Organic Chemical · Pharmacologic Substance
T2	CHEM 59 71	Dexametasona
#2	AnnotatorNotes T2	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T3	CHEM 82 92	Elotuzumab
#3	AnnotatorNotes T3	C1832049; elotuzumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T4	DISO 99 115	mieloma múltiple
#4	AnnotatorNotes T4	C0026764; Multiple Myeloma; Neoplastic Process
T5	PROC 165 200	Ensayo fase 2 abierto, aleatorizado
T6	CHEM 205 217	Pomalidomida
#5	AnnotatorNotes T6	C2347624; pomalidomide; Organic Chemical · Pharmacologic Substance
T7	CHEM 218 230	Dexametasona
#6	AnnotatorNotes T7	C0011777; dexamethasone; Organic Chemical · Pharmacologic Substance
T8	CHEM 241 251	Elotuzumab
#7	AnnotatorNotes T8	C1832049; elotuzumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	DISO 258 286	mieloma múltiple en recidiva
#8	AnnotatorNotes T9	C2349261; Relapse multiple myeloma; Neoplastic Process
T10	DISO 324 340	Mieloma múltiple
#9	AnnotatorNotes T10	C0026764; Multiple Myeloma; Neoplastic Process
T11	DISO 367 395	Mieloma Múltiple en recidiva
#10	AnnotatorNotes T11	C2349261; Relapse multiple myeloma; Neoplastic Process
T12	PROC 454 465	tratamiento
#11	AnnotatorNotes T12	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T13	CHEM 533 545	lenalidomida
#12	AnnotatorNotes T13	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T14	CHEM 551 575	inhibidor del proteosoma
#13	AnnotatorNotes T14	C1443643; Proteasome inhibitor; Pharmacologic Substance
T15	DISO 603 619	Mieloma múltiple
#14	AnnotatorNotes T15	C0026764; Multiple Myeloma; Neoplastic Process
T16	CHEM 693 716	inhibidor de proteosoma
#15	AnnotatorNotes T16	C1443643; Proteasome inhibitor; Pharmacologic Substance
T17	CHEM 719 731	lenalidomida
#16	AnnotatorNotes T17	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T18	PROC 747 758	tratamiento
#17	AnnotatorNotes T18	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T19	PROC 855 866	tratamiento
#18	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	CHEM 878 902	inhibidor del proteosoma
#19	AnnotatorNotes T20	C1443643; Proteasome inhibitor; Pharmacologic Substance
T21	CHEM 905 917	lenalidomida
#20	AnnotatorNotes T21	C1144149; lenalidomide; Organic Chemical · Pharmacologic Substance
T22	PROC 1002 1013	tratamiento
#21	AnnotatorNotes T22	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T23	DISO 1020 1038	Enfermedad medible
#22	AnnotatorNotes T23	C1513041; Measurable Disease; Disease or Syndrome
T24	DISO 1158 1196	Leucemia activa de células plasmáticas
T25	ANAT 1177 1196	células plasmáticas
#23	AnnotatorNotes T25	C0032112; Plasma Cells; Cell
T26	PROC 1202 1213	Tratamiento
#24	AnnotatorNotes T26	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T27	CHEM 1225 1237	pomalidomida
#25	AnnotatorNotes T27	C2347624; pomalidomide; Organic Chemical · Pharmacologic Substance
T28	DISO 1242 1260	Incapaz de tolerar
T29	PROC 1264 1289	profilaxis tromboembólica
T30	PROC 1313 1332	Trasplante autólogo
#26	AnnotatorNotes T30	C0040736; Transplantation, Autologous; Therapeutic or Preventive Procedure
T31	ANAT 1343 1379	células progenitoras hematopoyéticas
#27	AnnotatorNotes T31	C0018956; Hematopoietic stem cells; Cell
T32	CHEM 1444 1451	fármaco
#28	AnnotatorNotes T32	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T33	DISO 1468 1477	Infección
#29	AnnotatorNotes T33	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T34	DISO 1497 1522	Hepatitis activa A, B o C
T35	PROC 130 141	tratamiento
#30	AnnotatorNotes T35	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T36	DISO 1491 1494	VIH
#31	AnnotatorNotes T36	C0458074; Human immunodeficiency virus (HIV) status; Finding
T37	Date 13 17	2014
T38	Neg_cue 78 81	sin
T39	Neg_cue 237 240	sin
T40	LIVB 763 772	Pacientes
#32	AnnotatorNotes T40	C0030705; Patients; Patient or Disabled Group
T41	Duration 960 967	6 meses
T44	Duration 1395 1409	las 12 semanas
T45	CONC 1427 1440	primera dosis
T48	PHYS 1364 1379	hematopoyéticas
#33	AnnotatorNotes T48	C0018951; Hematopoiesis; Organ or Tissue Function
T42	PROC 1060 1076	Estado funcional
#34	AnnotatorNotes T42	C4525818; Clinical Performance Status; Health Care Activity | C3694602; functional status of patient; Therapeutic or Preventive Procedure
T43	DISO 637 645	recidiva
#35	AnnotatorNotes T43	C2825055; Recurrence (disease attribute); Pathologic Function
T46	DISO 776 784	recidiva
#36	AnnotatorNotes T46	C2825055; Recurrence (disease attribute); Pathologic Function
A1	Assertion T3 Negated
A2	Assertion T8 Negated
A3	Status T12 History_of
A4	Status T13 History_of
A5	Status T14 History_of
A6	Status T19 History_of
A7	Status T20 History_of
A8	Status T21 History_of
A9	Status T22 History_of
A10	Status T26 History_of
A11	Status T27 History_of
A12	Status T30 History_of
A13	Status T33 History_of
A14	Status T36 History_of
A15	Status T34 History_of
#37	AnnotatorNotes T5	C0282460; Phase 2 Clinical Trials; Research Activity + C0034656; Randomization; Research Activity
#38	AnnotatorNotes T24	C0023484; Leukemia, Plasma Cell; Neoplastic Process
#39	AnnotatorNotes T28	C0277585; Intolerance to drug; Pathologic Function
#40	AnnotatorNotes T34	C0744827; hepatitis active; Finding + C0019159; Hepatitis A; Disease or Syndrome + C0744829; HEPATITIS B ACTIVE; Disease or Syndrome + C0019196; Hepatitis C; Disease or Syndrome
R1	Negation Arg1:T38 Arg2:T3	
R2	Negation Arg1:T39 Arg2:T8	
R3	Combined_with Arg1:T1 Arg2:T2	
R4	Combined_with Arg1:T6 Arg2:T7	
R5	Combined_with Arg1:T2 Arg2:T3	
T47	Quantifier_or_Qualifier 116 141	resistente al tratamiento
#41	AnnotatorNotes T47	C0205269; Unresponsive to Treatment; Functional Concept
R6	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T47	
T49	Quantifier_or_Qualifier 289 300	refractario
#42	AnnotatorNotes T49	C0205269; Unresponsive to Treatment; Functional Concept
R7	Combined_with Arg1:T7 Arg2:T8	
R8	Has_Quantifier_or_Qualifier Arg1:T9 Arg2:T49	
T50	Quantifier_or_Qualifier 398 409	refractario
#43	AnnotatorNotes T50	C0205269; Unresponsive to Treatment; Functional Concept
R9	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T50	
T51	Quantifier_or_Qualifier 440 450	≥ 2 líneas
R10	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T51	
T52	Quantifier_or_Qualifier 499 516	al menos 2 ciclos
R11	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T52	
R12	Combined_with Arg1:T13 Arg2:T14	
T53	Quantifier_or_Qualifier 576 580	solo
R13	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T53	
R14	Used_for Arg1:T13 Arg2:T12	
R15	Used_for Arg1:T14 Arg2:T12	
T54	Quantifier_or_Qualifier 620 631	refractario
#44	AnnotatorNotes T54	C0205269; Unresponsive to Treatment; Functional Concept
T55	Quantifier_or_Qualifier 648 659	refractario
#45	AnnotatorNotes T55	C0205269; Unresponsive to Treatment; Functional Concept
R16	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T54	
R17	Before Arg1:T15 Arg2:T43	
R19	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T55	
T56	Quantifier_or_Qualifier 676 687	Refractario
#46	AnnotatorNotes T56	C0205269; Unresponsive to Treatment; Functional Concept
T57	Observation 787 799	refractarios
#47	AnnotatorNotes T57	C0438286; Absent response to treatment; Finding 
R18	Experiences Arg1:T40 Arg2:T46	
R20	Experiences Arg1:T40 Arg2:T57	
T58	Quantifier_or_Qualifier 821 833	al menos una
T59	Observation 834 851	respuesta parcial
#48	AnnotatorNotes T59	C1521726; partial response; Finding
R21	Has_Quantifier_or_Qualifier Arg1:T59 Arg2:T58	
R22	Overlap Arg1:T59 Arg2:T19	
R23	Used_for Arg1:T20 Arg2:T19	
R24	Used_for Arg1:T21 Arg2:T19	
R25	Experiences Arg1:T40 Arg2:T59	
R26	Before Arg1:T59 Arg2:T46	
R27	Before Arg1:T59 Arg2:T57	
R28	Experiences Arg1:T40 Arg2:T19	
R29	Combined_with Arg1:T20 Arg2:T21	
R30	Experiences Arg1:T40 Arg2:T22	
T60	Observation 977 989	refractarios
#49	AnnotatorNotes T60	C0438286; Absent response to treatment; Finding
R31	Overlap Arg1:T60 Arg2:T22	
R32	Experiences Arg1:T40 Arg2:T60	
T61	Observation 933 944	progresaron
#50	AnnotatorNotes T61	C1457868; Worse; Finding
R34	After Arg1:T61 Arg2:T41	
R35	Overlap Arg1:T61 Arg2:T60	
R36	Before Arg1:T19 Arg2:T61	
R33	Experiences Arg1:T40 Arg2:T61	
T62	PROC 1045 1054	selección
#51	AnnotatorNotes T62	C0242802; Patient Selection; Research Activity
R37	Overlap Arg1:T23 Arg2:T62	
T63	CONC 1081 1115	Eastern Cooperative Oncology Group
#52	AnnotatorNotes T63	C1520224; ECOG performance status; Intellectual Product
T64	CONC 1117 1121	ECOG
#53	AnnotatorNotes T64	C1520224; ECOG performance status; Intellectual Product
R38	Used_for Arg1:T63 Arg2:T42	
R39	Used_for Arg1:T64 Arg2:T42	
T65	Result_or_Value 1123 1126	≤ 2
R40	Has_Result_or_Value Arg1:T63 Arg2:T65	
R41	Has_Result_or_Value Arg1:T64 Arg2:T65	
R42	Location_of Arg1:T25 Arg2:T24	
R43	Used_for Arg1:T27 Arg2:T26	
R44	Causes Arg1:T29 Arg2:T28	
#54	AnnotatorNotes T29	C0199242; Administration of prophylactic anticoagulant; Therapeutic or Preventive Procedure
T66	PROC 1301 1308	estudio
#55	AnnotatorNotes T66	C0008976; Clinical Trials; Research Activity
R45	Overlap Arg1:T29 Arg2:T66	
R46	Overlap Arg1:T28 Arg2:T66	
R47	Overlap Arg1:T30 Arg2:T44	
R48	Before Arg1:T30 Arg2:T45	
R49	Has_Dose_or_Strength Arg1:T32 Arg2:T45	
R51	Causes Arg1:T36 Arg2:T33	
R52	Causes Arg1:T34 Arg2:T33	
T67	Quantifier_or_Qualifier 517 529	consecutivos
#56	AnnotatorNotes T67	C1707491; Consecutive; Qualitative Concept
R53	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T67	
#57	AnnotatorNotes T53	C0205171; Singular; Quantitative Concept
#58	AnnotatorNotes R49	(?)
#59	AnnotatorNotes T45	C5236155; Date of First Dose; Temporal Concept
A16	Experiencer T40 Patient
